Experimental Neurosurgery, Goethe University Hospital Frankfurt/Main, Frankfurt, Germany.
Experimental Cancer Research in Pediatrics, Goethe University Hospital Frankfurt/Main, Frankfurt, Germany.
Autophagy. 2021 Nov;17(11):3424-3443. doi: 10.1080/15548627.2021.1874208. Epub 2021 Jan 19.
Increasing evidence suggests that induction of lethal macroautophagy/autophagy carries potential significance for the treatment of glioblastoma (GBM). In continuation of previous work, we demonstrate that pimozide and loperamide trigger an ATG5- and ATG7 (autophagy related 5 and 7)-dependent type of cell death that is significantly reduced with cathepsin inhibitors and the lipid reactive oxygen species (ROS) scavenger α-tocopherol in MZ-54 GBM cells. Global proteomic analysis after treatment with both drugs also revealed an increase of proteins related to lipid and cholesterol metabolic processes. These changes were accompanied by a massive accumulation of cholesterol and other lipids in the lysosomal compartment, indicative of impaired lipid transport/degradation. In line with these observations, pimozide and loperamide treatment were associated with a pronounced increase of bioactive sphingolipids including ceramides, glucosylceramides and sphingoid bases measured by targeted lipidomic analysis. Furthermore, pimozide and loperamide inhibited the activity of SMPD1/ASM (sphingomyelin phosphodiesterase 1) and promoted induction of lysosomal membrane permeabilization (LMP), as well as release of CTSB (cathepsin B) into the cytosol in MZ-54 wild-type (WT) cells. Whereas LMP and cell death were significantly attenuated in and knockout (KO) cells, both events were enhanced by depletion of the lysophagy receptor VCP (valosin containing protein), supporting a pro-survival function of lysophagy under these conditions. Collectively, our data suggest that pimozide and loperamide-driven autophagy and lipotoxicity synergize to induce LMP and cell death. The results also support the notion that simultaneous overactivation of autophagy and induction of LMP represents a promising approach for the treatment of GBM.: ACD: autophagic cell death; AKT1: AKT serine/threonine kinase 1; ATG5: autophagy related 5; ATG7: autophagy related 7; ATG14: autophagy related 14; CERS1: ceramide synthase 1; CTSB: cathepsin B; CYBB/NOX2: cytochrome b-245 beta chain; ER: endoplasmatic reticulum; FBS: fetal bovine serum; GBM: glioblastoma; GO: gene ontology; HTR7/5-HT7: 5-hydroxytryptamine receptor 7; KD: knockdown; KO: knockout; LAMP1: lysosomal associated membrane protein 1; LAP: LC3-associated phagocytosis; LMP: lysosomal membrane permeabilization; MAP1LC3B: microtubule associated protein 1 light chain 3 beta; MTOR: mechanistic target of rapamycin kinase; RB1CC1: RB1 inducible coiled-coil 1; ROS: reactive oxygen species; RPS6: ribosomal protein S6; SMPD1/ASM: sphingomyelin phosphodiesterase 1; VCP/p97: valosin containing protein; WT: wild-type.
越来越多的证据表明,诱导致死性巨自噬/自噬对胶质母细胞瘤(GBM)的治疗具有潜在意义。在之前工作的基础上,我们证明匹莫齐特和洛哌丁胺触发了一种依赖 ATG5 和 ATG7(自噬相关 5 和 7)的细胞死亡类型,这种细胞死亡在 MZ-54 GBM 细胞中被组织蛋白酶抑制剂和脂质活性氧(ROS)清除剂 α-生育酚显著减少。用这两种药物处理后的全蛋白质组分析也揭示了与脂质和胆固醇代谢过程相关的蛋白质增加。这些变化伴随着胆固醇和其他脂质在溶酶体隔室中的大量积累,表明脂质转运/降解受损。与这些观察结果一致的是,匹莫齐特和洛哌丁胺治疗与生物活性鞘脂的显著增加有关,包括通过靶向脂质组学分析测量的神经酰胺、葡糖神经酰胺和神经鞘氨醇碱基。此外,匹莫齐特和洛哌丁胺抑制了 SMPD1/ASM(鞘磷脂磷酸二酯酶 1)的活性,并促进了 MZ-54 野生型(WT)细胞中的溶酶体膜通透性(LMP)诱导和组织蛋白酶 B(CTSB)向细胞质的释放。然而,在 和 基因敲除(KO)细胞中,LMP 和细胞死亡明显减弱,而在 VCP(包含 valosin 的蛋白)溶酶体吞噬受体耗竭的情况下,这两种事件都被增强,支持了在这些条件下溶酶体吞噬的促生存功能。总的来说,我们的数据表明,匹莫齐特和洛哌丁胺驱动的自噬和脂肪毒性协同诱导 LMP 和细胞死亡。研究结果还支持同时过度激活自噬和诱导 LMP 代表治疗 GBM 的一种很有前途的方法的观点。: ACD:自噬细胞死亡;AKT1:AKT 丝氨酸/苏氨酸激酶 1;ATG5:自噬相关 5;ATG7:自噬相关 7;ATG14:自噬相关 14;CERS1:神经酰胺合酶 1;CTSB:组织蛋白酶 B;CYBB/NOX2:细胞色素 b-245 亚基;ER:内质网;FBS:胎牛血清;GBM:胶质母细胞瘤;GO:基因本体论;HTR7/5-HT7:5-羟色胺受体 7;KD:敲低;KO:基因敲除;LAMP1:溶酶体相关膜蛋白 1;LAP:LC3 相关吞噬作用;LMP:溶酶体膜通透性;MAP1LC3B:微管相关蛋白 1 轻链 3β;MTOR:雷帕霉素靶蛋白激酶;RB1CC1:RB1 诱导卷曲螺旋 1;ROS:活性氧;RPS6:核糖体蛋白 S6;SMPD1/ASM:鞘磷脂磷酸二酯酶 1;VCP/p97:包含 valosin 的蛋白;WT:野生型。